Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Valstar
(United States) [Available]Synonyms :
valrubicin
Class :
Antineoplastic Agent
Dosage Forms & Strengths  Â
Intravesical solution  Â
40mg/ml  Â
800
mg
intravesical once per week for about six weeks
Note:
Delayed administration at least two weeks after transurethral resection or fulguration
Retain the drug for two hours in bladder before voiding
After 2hrs patients should void
Dose Adjustments
Renal Dose Adjustments:
No data available
Liver Dose Adjustments:
No data available
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
measles, mumps, rubella, and varicella vaccine, live (Rx)
may diminish the therapeutic effect
measles mumps and rubella vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
smallpox (vaccinia) vaccine, live
may diminish the therapeutic effect
may diminish the therapeutic effect
spironolactone and hydrochlorothiazide
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
may enhance the toxic effects of the other by pharmacodynamic synergism
when both drugs are combined, there may be increased toxicity of valrubicin    
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk or severity of infection  
may diminish the pharmacodynamic antagonistic effect of each other when combined
measles, mumps, rubella, and varicella vaccine, live 
may diminish the pharmacodynamic antagonistic effect of each other when combined
measles mumps and rubella vaccine, live
may diminish the pharmacodynamic antagonistic effect of each other when combined
may diminish the pharmacodynamic antagonistic effect of each other when combined
smallpox (vaccinia) vaccine, live
may diminish the pharmacodynamic antagonistic effect of each other when combined
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk or severity of infection  
when both drugs are combined, there may be an increased risk or severity of adverse effects 
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
it may increase the levels of serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may reduce the therapeutic effect of typhoid Vaccine
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the serum concentration
may decrease the serum concentration
Actions and Spectrum: Â
Action:Â
Valrubicin disrupts DNA structure by inserting between base pairs, hindering replication and transcription.Â
Valrubicin inhibits topoisomerase II, essential for DNA replication and repair, leading to DNA breaks accumulation and enhancing its anticancer effects.Â
Spectrum: Â
Valrubicin treats superficial bladder cancer, especially carcinoma in situ, unresponsive to other treatments, by being directly instilled into the bladder mucosa.Â
Frequency defined  Â
>10%  Â
Bladder pain  Â
Bladder spasm  Â
Cystitis  Â
Hematuria  Â
Urinary incontinence  Â
UTI   Â
Urinary urgency  Â
1-10%  Â
Anemia  Â
Back pain  Â
Chest pain  Â
Diarrhea  Â
Headache  Â
Malaise  Â
Pneumonia  Â
Urinary retention  Â
Vomiting  Â
Vasodilation   Â
Frequency not defined  Â
Asthenia   Â
Contraindication/Caution: Â
Contraindications Â
HypersensitivityÂ
MyelosuppressionÂ
Active InfectionsÂ
Cautions Â
Cardiac FunctionÂ
Bone Marrow SuppressionÂ
Urinary Tract InfectionsÂ
Liver diseaseÂ
Pregnancy warnings:    Â
US FDA pregnancy category: C Â
Breastfeeding warnings: Â
The release of the drug into the human breastmilk is known  Â
Pregnancy Categories:      Â
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first trimester or the later trimester      Â
<b>Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women      Â
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women      Â
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits      Â
Category X: Drugs listed in this category outweigh risks over benefits Hence these categories of drugs need to be avoided by pregnant women      Â
Category N: There is no data available for the drug under this category   Â
Pharmacology: Â
Valrubicin disrupts DNA structure by intercalating between DNA base pairs.Â
Pharmacodynamics: Â
Valrubicin kills cancer cells by disrupting DNA processes, inhibiting growth, and causing cell death. Â
Valrubicin triggers programmed cell death in cancer cells through DNA damage accumulation and signaling pathway activation.Â
Pharmacokinetics: Â
AbsorptionÂ
To minimise absorption elsewhere, valrubicin is administered directly into the bladder.Â
Distribution Â
It stays mainly in the bladder with minimal distribution throughout the body.Â
Metabolism Â
The drug metabolism occurs in the liver.Â
Excretion and EliminationÂ
The drug is excreted primarily through urine, with a small amount in feces.Â
Administration:Â
The administration of valrubicin occurs through the process of intravesical instillation.Â
Patient Information Leaflet  Â
Generic Name: valrubicin (Rx)  Â
Why do we use valrubicin? Â
Valrubicin is FDA-approved for the treatment of Bacillus Calmette-GuĂ©rin (BCG)-refractory carcinoma in situ of the urinary bladder.Â
It is used in the treatment of cancer of the bladder.Â